Navigation Links
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Date:12/11/2007

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV) will be presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007. The abstract titles and abbreviated study summaries are described below. The full conference abstracts are currently available for download in PDF format in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm . The full scientific presentations will be available for download in PDF format following the conference in the "Product Pipeline" section of Pharmasset's website at http://www.pharmasset.com/pipeline .

Clevudine was Superior to Lamivudine in the Patients with HBeAg(+) Chronic Hepatitis B. GK Lau, et al.

Abstract Summary: The aim of this study is to compare the efficacy and safety of clevudine versus lamivudine for 48 weeks in chronic hepatitis B (CHB) e-antigen positive (HBeAg(+)) patients in a randomized and blinded manner. Based on the preliminary results from 22 patients (11 clevudine, 11 lamivudine), 48-weeks of dosing with clevudine 30mg showed superior viral suppression to lamivudine 100mg without the emergence of viral breakthrough in HBeAg(+) CHB patients. At week 48, serum HBV DNA levels were below the level of detection (<300 copies/mL) in 82% of patients in the cl
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... -- STAAR Surgical Company (NASDAQ: STAA ), ... ophthalmic products, today announced that it will participate in ... financial results and business developments with investors and interested ... 38 th Annual Deutsche Bank 2013 Healthcare Conference ... Waterfront Hotel on Wednesday, May 29, 2013 at 10:40 ...
(Date:5/21/2013)... LEESBURG, Va. , May 21, 2013 /PRNewswire/ ... than 22,000 pharmacies nationwide, announces today the publication ... Healing America,s Post-Reform Health Care System. The white ... health, reducing costs, and seeks public engagement to ... Personalized Pharmacist Care refers to a range ...
Breaking Medicine Technology:Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Young drivers ... higher risk of getting into car crashes, but Australian ... sleep on weekends puts them in even greater danger ... another challenge to adolescents that comes with lack of ... of the Center for Injury Research and Prevention at ...
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Long-acting ... chronic obstructive pulmonary disease (COPD) may raise the ... new large Canadian study reveals. The finding ... prescribed long-acting bronchodilators -- either anticholinergics (such as ... are commonly used to relieve the shortness of ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... (HealthDay News) -- Racial disparities exist in the treatment ... United States, according to a large new study. ... part of their initial treatment, researchers found that blacks ... surgery in the early stages of the disease. Hispanics ... and stage 2 disease than white patients. "In ...
(Date:5/21/2013)... The surgical management of non-small cell lung cancer ... race of the patient, according to a new study., ... and Stage II NSCLC is surgery," said researcher Jayanth ... Omaha, Nebraska. "In our study of more than 1,200,000 ... years 2000 and 2010, we found statistically significant racial ...
Breaking Medicine News(10 mins):Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... The first results of the first European survey of cancer ... 6th congress of the European Federation of Chapters of the ... surveys have looked at the overall management of pain in ... look in detail at Breakthrough Cancer Pain (BTCP) from a ...
... ... Proactive Wellness Centers, PLC -- a leading Anti-Aging Practice, is the featured speaker at ... in Northern Virginia. , ... Sterling, VA (PRWEB) September 11, 2009 -- Most women understand that health factors ...
... ... specialist Flintec has recruited eight new software and electronic developers to ... equipment is Flintec,s fastest growing area of business. Increasing numbers of ... build the precision measuring systems at the heart of their life-saving ...
... , , NEW YORK, Sept. ... and The Mount Sinai Medical Center describe the Community Diabetes ... outreach program which was designed specifically for people from the vulnerable ... Twenty-five patients from The Mount Sinai Medical Center were randomly ...
... , , , ... industry leader, declared his support for H.R. 1891, a House bill ... deduction. Roeser is Senior Vice President of Marketing and Operations for ... -- one of the nation,s largest and most experienced long-term care ...
... , VOORHEES, N.J., Sept. 10 Angioedema is ... organs, and airway, causing discomfort and even death as a result ... the prevention and treatment of angioedema, and new therapies are being ... patient population. , , To address the need ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 2Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 4Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:Industry Leader Praises Health Reform Bill that Provides 50% Tax Deduction for Long-Term Care Premiums 2Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2
... The BladderScan BVM 6500 ... noninvasively to determine UEBW ... and bladder volume using ... BVM 6500 was designed ...
... Titan™ Inflatable Penile Prosthesis (IPP) ... to be surgically implanted into ... of erectile dysfunction (also known ... the patient with voluntary control ...
... Alpha I continues to be a proven, ... Alpha I to have mechanical reliability rates ... first-time implants. ioflex material contributes to excellent ... Thats because Bioflex: ,Provides maximum, controlled girth ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
Medicine Products: